Glenmark gets FDA’s blessing for generic Vesicare
Glenmark Pharmaceuticals has received the green light from the Food and Drug Administration for solifenacin succinate tablets, in 5 mg and 10 mg dosages strengths.
Solifenacin succinate tablets are the generic of Astellas Pharma’s Vesicare tablets, 5 mg and 10 mg.
The product had a market value of roughly $942.7 million for the 12 month period ending March 2019, according to IQVIA.
Solifenacin succinate tablets are the generic of Astellas Pharma’s Vesicare tablets, 5 mg and 10 mg.
The product had a market value of roughly $942.7 million for the 12 month period ending March 2019, according to IQVIA.